Citi says Hutchmed-GSK deal validates platform pre-clinical
Citi analysts say Hutchmed’s licensing deal with GSK appears to validate the company’s drug candidate platform ahead of clinical trials. The deal could be worth up to US$1.295 billion, excluding additional components.
Hutchmed (China)'s deal with GSK appears to validate a specific drug candidate platform of the Hong Kong-based biopharmaceutical company before it enters clinical trials, say Citi analysts in a note.
Hutchmed entered an licensing deal with GSK that could be worth up to US$1.295 billion, excluding r…